English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)
Press review

June 28, 2024 - ITALFARMACO

Artificial intelligence to speed drug discovery breakthroughs


March 21, 2024 - Business Wire

Italfarmaco receives FDA approval for givinostat in Duchenne muscular dystrophy (DMD)


March 19, 2024 - Business Wire

Italfarmaco Publishes in The Lancet Neurology results from Phase 3 EPIDYS Study in Duchenne Muscular Dystrophy (DMD)


September 05, 2023 - Business Wire

Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy


June 29, 2023 - Business Wire

Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review


April 01, 2023 - Il Sole 24 Ore

De Santis: we need to train new skills for competition


June 25, 2022 - Business Wire

Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy


June 26, 2021 - Business Wire

Italfarmaco Announces Topline Data from Phase 2 Trial with Givinostat in Patients with Becker Muscular Dystrophy


March 25, 2021 - ITALFARMACO

Italfarmaco's commitment against Covid-19


March 16, 2021 - ITALFARMACO

Italfarmaco Group adds innovative Alzheimer’s disease therapy to its neurology-based product portfolio


February 22, 2021 - Business Wire

Italfarmaco provides an update on the clinical development program of Givinostat in Duchenne Muscular Dystrophy


October 12, 2020 - PharmaStar

Duchenne, givinostat riceve da Fda lo status di farmaco per malattia pediatrica rara.


October 12, 2020 - ITALFARMACO

Italfarmaco Receives FDA Rare Pediatric Disease Designation for Givinostat in Duchenne Muscular Dystrophy…


June 12, 2020 - interprogetti editori

Combination Products integrated into the corporate Quality System of the Pharmaceutical Industries


May 26, 2020 - Il Giorno (edizione Milano)

Virus and coagulation risk: x-ray medical records - Interview with Dr. Paolo Zamboardi - Italfarmaco Spa


May 14, 2020 - adnkronos

Coronavirus, Italfarmaco donates 250 thousand Ppe to the Lombardy Region


April 30, 2020 - Il Sole 24 Ore

Confindustria, varata la squadra di presidenza. Bonomi: caos misure fase 2, incerte e contraddittorie. Dieci vicepresidenti elettivi e tre di diritto.


April 30, 2020 - la Repubblica

Confindustria, la squadra di Bonomi. Gubitosi e Beltrame vicepreseidenti.


April 30, 2020 - la Repubblica

Coronavirus the first Italian registry on the link with thrombosis


April 27, 2020 - PharmaStar

Thromboembolic complications from Covid-19, the first Italian register starts


April 27, 2020 - BusinessWire

Italfarmaco Provides Update on Advanced-Stage Clinical Development Program with Givinostat in Duchenne Muscular Dystrophy


March 26, 2020 - Aboutpharma Online

Italian Pharmaceutical: from 13 companies support for family doctors


February 12, 2020 - BeBeez

Italfarmaco and Rottapharm Biotech have launched AurorA Science their vehicle dedicated to investing in startups


November 08, 2019 - PHARMACEUTIQUES

"Italian Success Story" of the magazine PHARMACEUTIQUES, n ° 270, Oct 2019


August 01, 2019 - ITALFARMACO

Italfarmaco Enters Binding Term Sheet Agreement with Neupharma for an Exclusive Option to Develop and Commercialize Inhaled Teicoplanin


April 02, 2019 - Il giorno Milano

Biosimilar drugs, new frontier


February 28, 2019 - ITFPHARMA

ITF Pharma has been named an honoree for the 2018 Patient Impact Award, presented by Life Sciences Pennsylvania, for the successful launch and approval of TIGLUTIK


November 30, 2018 - Adnkronos

The project: make the first move take care of your bones. The "awareness" initiative on osteoporosis is supported by Abiogen and Italfarmaco and will interest 11 scientific societies involved in the study of metabolic bone diseases.


September 06, 2018 - ITFPHARMA

ITF PHARMA announces FDA approval of TIGLUTIK™ (riluzole) oral suspension for the tratment of amyotrophic lateral sclerosis (ALS)


September 06, 2018 - ABOUTPHARMA ONLINE

Sla, Fda approva riluzolo di Italfarmaco


June 28, 2017 - Il Giorno Milano

Malattia rara. Un accordo da 5,6 milioni per la ricerca


March 27, 2017 - Il Sole24 Ore

Più calcio e vitamina D per ridurre le fratture da osteoporosi e far risparmiare il Ssn


March 25, 2015 - Pharmakronos

L'accordo Chemi-Teva dà i suoi frutti


February 25, 2015 - Pharmastar

Distrofia di Duchenne, bene in fase II il givinostat, farmaco di ricerca Italfarmaco


March 01, 2014 - Espansione

L'industria farmaceutica in un mondo che cambia - Tavola Rotonda. Il settore farmaceutico, tra attualità e prospettive.


December 13, 2013 - Helsinn.com

Helsinn and Italfarmaco reinforce their alliance through the grant of rights to phase-III ghrelin receptor agonist Anamorelin in Italy


November 27, 2013 - Aziende storiche di Milano

Presentation of book "Aziende storiche di Milano" (Historical Companies of Milan), edited by the Circolo Filologico Milanese, with the participation of the Chamber of Commerce of Milan and with the sponsorship of Expo 2015. The book intends to be an acknowledgement to Milanese Companies with the longest corporate history which, with entrepreneurial continuity, keep pursuing the development and growth of their activity. Italfarmaco SpA, founded in 1938, is deservedly counted among them, and the book contains a dedicated section.